

RESEARCH ARTICLE

Open Access



Costs of multimorbidity: a systematic review and meta-analyses

Phuong Bich Tran^{1*}, Joseph Kazibwe^{2,3}, Georgios F. Nikolaidis⁴, Ismo Linnosmaa⁵, Mieke Rijken^{5,6} and Josefien van Olmen¹

Abstract

Background: Multimorbidity is a rising global phenomenon, placing strains on countries' population health and finances. This systematic review provides insight into the costs of multimorbidity through addressing the following primary and secondary research questions: What evidence exists on the costs of multimorbidity? How do costs of specific disease combinations vary across countries? How do multimorbidity costs vary across disease combinations? What "cost ingredients" are most commonly included in these multimorbidity studies?

Methods: We conducted a systematic review (PROSPERO: CRD42020204871) of studies published from January 2010 to January 2022, which reported on costs associated with combinations of at least two specified conditions. Systematic string-based searches were conducted in MEDLINE, The Cochrane Library, SCOPUS, Global Health, Web of Science, and Business Source Complete. We explored the association between costs of multimorbidity and country Gross Domestic Product (GDP) per capita using a linear mixed model with random intercept. Annual mean direct medical costs per capita were pooled in fixed-effects meta-analyses for each of the frequently reported dyads. Costs are reported in 2021 International Dollars (I\$).

Results: Fifty-nine studies were included in the review, the majority of which were from high-income countries, particularly the United States. (1) Reported annual costs of multimorbidity per person ranged from I\$800 to I\$150,000, depending on disease combination, country, cost ingredients, and other study characteristics. (2) Our results further demonstrated that increased country GDP per capita was associated with higher costs of multimorbidity. (3) Meta-analyses of 15 studies showed that on average, dyads which featured Hypertension were among the least expensive to manage, with the most expensive dyads being Respiratory and Mental Health condition (I\$36,840), Diabetes and Heart/vascular condition (I\$37,090), and Cancer and Mental Health condition in the first year after cancer diagnosis (I\$85,820). (4) Most studies reported only direct medical costs, such as costs of hospitalization, outpatient care, emergency care, and drugs.

Conclusions: Multimorbidity imposes a large economic burden on both the health system and society, most notably for patients with cancer and mental health condition in the first year after cancer diagnosis. Whether the cost of a disease combination is more or less than the additive costs of the component diseases needs to be further explored. Multimorbidity costing studies typically consider only a limited number of disease combinations, and few have been conducted in low- and middle-income countries and Europe. Rigorous and standardized methods of data collection

*Correspondence: phuong.tran@uantwerpen.be

¹ Department of Family Medicine and Population Health, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
Full list of author information is available at the end of the article



and costing for multimorbidity should be developed to provide more comprehensive and comparable evidence for the costs of multimorbidity.

Keywords: Multimorbidity, Chronic diseases, Cost, Economic burden, Health system

Background

Across the world, the prevalence of multimorbidity is increasing, especially among older populations. Studies reporting the prevalence of multimorbidity have given rates ranging from 32% of patients attending general practices in the Netherlands [1] to 99% of patients attending ambulatory care in Canada [2]. Across Europe, many countries have seen 40–60% of those aged 50 years or older living with multimorbidity [3–5]. In low- and middle-income countries (LMICs), the prevalence of multimorbidity ranges from 3.2 to 90.5% depending on the age group [6]. While multimorbidity risk increases with age, in some LMICs, more cases of multimorbidity can be found among those under the age of 65, due to expansive population pyramids [7] and a higher prevalence of risk factors [8, 9]. Multimorbidity is thus a major public health problem to be urgently addressed.

Beyond the prevalence of the individual “combiners” — conditions found in a multimorbidity combination — the prevalence of a disease combination is typically linked to both the age structure of the population [10] and behavioral risk factors [11]. Common combiners — including diabetes, hypertension, osteoarthritis, and mental health conditions such as depression — usually appear across different disease combinations [12–14]. Epidemiological research on the distribution and underlying determinants of multimorbidity is still evolving [7], yet its impact on healthcare systems and societies is becoming increasingly clear.

Treating multimorbidity is generally more complex than treating single diseases, thereby increasing the demand for healthcare resources. Such treatment often requires additional customization for the patient and often lasts longer [8, 15, 16]. Many multimorbid patients also experience functional limitations and are required to spend more time visiting healthcare providers. It is common for these issues to interfere with a patient’s work, which in turn contributes to societal costs [17]. Consequently, as the prevalence of multimorbidity continues to rise, countries face not only the challenges of providing quality multimorbidity care, but must also make preparations to shoulder the economic burden it brings about [18, 19].

While there is much research exploring costs associated with single chronic conditions, studies into multimorbidity costs are limited in scope and number. Among these studies, most have tended to focus on either the

number of conditions or the severity of multimorbidity, the latter typically estimated using measures such as the *Charlson Comorbidity Index* [20]. There have been two systematic reviews on the costs of multimorbidity per-disease-count, with inclusion periods of 1996–2013 and 1992–2010 [21, 22]. While both studies reported that patients with multimorbidity incurred higher costs than those without, neither explored the costs of specific disease combinations.

In line with global health priorities, we have reviewed the evidence on the costs of multimorbidity to address the question, “Which disease clusters result in the greatest costs?” [7]. In conducting the review, we further addressed the following primary research question (#1) and secondary research questions (#2–4):

- 1) What evidence exists on the costs of multimorbidity?
- 2) How do costs of specific disease combinations vary across countries?
- 3) How do multimorbidity costs vary across disease combinations?
- 4) What “cost ingredients” are most commonly included in these multimorbidity studies?

The findings of this review are important to disentangle our understanding of the economic burden of multimorbidity, which in turn will inform both the implementation of health interventions and the optimization of healthcare delivery.

Methods

We firstly conducted a systematic review applying a narrative synthesis of included studies, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [23]. Following this, we conducted meta-analyses including those studies which had provided comparable information. This review is registered with PROSPERO (*ref* CRD42020204871).

Databases and search terms

The initial search was conducted on 9 October 2020, with a follow-up search on 4 January 2022. Databases searched were *Web of Science*, *Global Health*, *MEDLINE*, *SCOPUS*, *The Cochrane Library*, and *Business Source Complete*. A snowballing technique was adopted to identify further articles from within the reference lists of eligible studies.

The database-specific search strings are detailed in Additional file 1 — Search strings.

Study selection

The search included all quantitative studies described in full-text papers, published in English between 1 January 2010 and 4 January 2022. Papers were eligible for inclusion if they reported the costs associated with the co-existence of at least two chronic conditions. We excluded studies not specifying combinations of chronic conditions and those which had estimated incremental costs only (for full list of exclusion criteria, see Fig. 1).

Following the removal of duplicates, articles were screened based upon their titles and abstracts, using Rayyan QCRI software [24] (phase 1). Articles were subsequently transferred to Endnote X9 for full-text screening and reference management (phase 2). Both screening phases were conducted by two authors (PT and JK) using a checklist (Additional file 2 — Screening checklists), and conflicts resolved with the senior author’s input (JVO).

Quality assessment

The quality of studies was assessed by two authors independently (PT and JK) using the Newcastle–Ottawa Quality Assessment Scale (NOS) [25]. In the case of


discrepancies, consensus was reached with input from other authors.

Data extraction and classification

A REDCap form, which had previously been piloted and refined, was used to facilitate the data extraction process. REDCap was chosen due to its level of data encryption, user-friendliness, and its capabilities for customization in data collection [26]. The following data were extracted: study characteristics, sample size, disease characteristics, care setting, and costs. The data cleaning process is presented in Additional file 3 — Data cleaning flow chart.

Cost parameter

This study’s primary outcome measure is the *average annual cost per patient per disease combination*, comprising of direct medical costs, direct non-medical costs, and indirect costs. Direct medical cost is the cost of a defined health service or intervention and all follow-up costs for medication and medical equipment (diagnostics, hospitalization, outpatient, emergency, drugs, and equipment) [27]. Direct non-medical cost is the cost incurred in the process of seeking and after receiving health services that are not involved in the direct purchasing of medical products or services (transportation/travel costs, food,



accommodation, and additional paid caregiver time) [27]. Indirect costs are those incurred as a result of losses from the disease(s) or disease management (time loss, wage loss, interest from debts/loans) [27]. Other terminologies are explained in Additional file 4 — Definition of terminologies. All costs are reported in 2021 International Dollars (denoted by I\$), which is a hypothetical currency with the same purchasing power in every country, using the US as a reference [28]. First, the reported cost was inflated to 2021 local currency unit [29]; then, it was converted to International Dollar using 2021 *Purchasing Power Parities (PPP)* [30].

The costing perspective is important in a costing study as it determines which costs are included (direct medical/non-medical, indirect costs), the source of data, and the scope of the study. The costing perspective may reflect a patient (often out-of-pocket), an organization (provider), a health system (public or private), or all of society [31]. This review includes all costing perspectives, but mainly reports on the health system perspective as it is accounted for in the majority of studies. The health system perspective entails formal direct medical costs paid for by third-party payers or by patients [32].

Analysis and presentation of results

To address research question 1, we tabulated all combinations of conditions and their costs as described in the studies. For one study that reported costs at baseline and follow-ups, costs were pooled to arrive at an average estimate [33].

Related conditions were grouped together. For example, *Type 1* and *Type 2 diabetes* were classified as “Diabetes”. *Mental disorder*, *anxiety disorder*, and *depression* were grouped as “Mental Health conditions”. *Asthma*, *chronic obstructive pulmonary disease (COPD)*, and *tuberculosis (TB)* were combined under the category “Respiratory diseases”. *Cardiovascular disease*, *coronary atherosclerosis*, *congestive heart failure*, *coronary heart disease*, *atrial fibrillation*, *coronary artery disease*, *peripheral artery disease*, *myocardial infarction*, *heart disease/failure*, *cerebrovascular disease*, *conduction disorder or cardiac dysrhythmia*, *valvular disease*, *peripheral vascular disorders*, and *pulmonary circulation disorders* were classified as “Heart/vascular conditions”. “Cancers” included *thyroid*, *stomach*, *breast*, *uterus*, *kidney*, *colon and rectum*, *esophagus*, *pancreas*, *head and neck*, *other gastrointestinal*, *liver*, *ovarian*, *multiple myeloma*, and *any malignancy/tumor*. Alternate groupings would have been possible, and those following a more treatment-focused perspective may have led to variation in results. However, we resorted to this approach in order to reduce the number of combinations and condense information for ease of interpretations. Grouping these conditions at an organ

system level makes sense from a health system/organizational perspective considering that they show similarities related to medical specialties. For example, *lung cancer* is grouped together with other cancer sites and not with the respiratory diseases, considering that cancers are treated by oncologists and most other (severe) lung or respiratory conditions are treated by pulmonologists. On the other hand, we categorized *hypertension* separately from the heart/vascular group as it is the leading metabolic risk factor globally [34]. Moreover, most studies also report hypertension separately; therefore, following this approach allowed for cross-comparison between studies. Lastly, we did not include stroke in the heart/vascular group as it is considered a chronic disease with acute exacerbations, in which the cascade of care is important in contextualizing the costs across the patient care pathway; therefore, the cost of stroke cannot be interpreted together with other heart/vascular conditions [35].

This resulted in six main disease categories: (1) Diabetes, (2) Heart/vascular conditions, (3) Respiratory diseases, (4) Cancers, (5) Mental Health conditions, and (6) Hypertension. The first four and mental health conditions are classified by the World Health Organization as major noncommunicable diseases (NCDs) [36].

Research question 2 aimed to contextualize the variability in costs using country GDP per capita in 2020 (latest available data) [37, 38]. For this analysis, we included only the most frequently reported dyads. We used the same study eligibility criteria as for the meta-analyses (see below), with several conditions relaxed. The criteria that studies must have had the same design, and reported measures of distribution and all-cause costs were relaxed, as we could control for these factors in the model. First, we ran a linear model with *annual mean direct medical costs per capita* as the dependent variable and *GDP per capita* as the independent variable taking on fixed effects. Subsequently, we incorporated different study characteristics as random effects. Potential study characteristics that may affect costs are study, study design, data source, and country. We performed log10 transformations on costs and GDP to normalize the distribution and to stabilize the variation within groups. After testing different models and observing variance, *p*-value and Akaike Information Criterion (AIC), the best fit model consisted of *GDP* as fixed effects and *study* and *data source* as random effects. The analysis was performed in RStudio version 2021.09.2 [39].

To compare the costs of disease combinations and to identify those that resulted in high costs (research question 3), meta-analyses were conducted for the most frequently reported dyads. Studies were categorized to ensure similarities within each sub-group meta-analysis. The criteria for homogeneity were (1) same cost

perspective and study design, (2) reporting annual mean direct medical cost, (3) reporting measures of distribution, (4) comparability of cost ingredients determined by recurring ingredients (hospitalization, outpatient care, emergency care, drugs), (5) studies assessed together having either all specified all-cause healthcare cost or not specified at all, and (6) studies that only assessed costs specific to the disease(s) of interest were not included. For studies that reported more than one estimate for the same dyad, these estimates were pooled before being entered into the meta-analysis — provided that the mean cost, its standard error, and the sample size corresponding to each were provided [40–42]. Where appropriate, costs per month or per 6 months were multiplied by 12 or 2, respectively, to arrive at the estimates for 12 months [40, 42, 43].

Mean cost data were meta-analyzed assuming a normal likelihood for study-specific mean costs. Despite the non-normal nature of healthcare costs [44], the distribution of sample mean costs will approximate a normal distribution as the number of studies increases due to the Central Limit Theorem. Given the low number of studies that were available for some disease combinations, a fixed-effects model was prioritized on practical grounds, acknowledging the strength of the imposed assumption (i.e., a common underlying true cost across all studies). Random-effects models were also attempted, noting that the low number of studies may lead to convergence issues

and unrealistic estimates of the between-study heterogeneity [45]. The extent of heterogeneity was estimated and presented by the means of I^2 [46]. All synthesis models were implemented in OpenBUGS version 3.2.3 [47] using three Markov Chain Monte Carlo chains with different starting values. Estimates were obtained from 70,000 iterations (including 20,000 burn-in). Convergence was checked using the Gelman-Rubin diagnostic, specifically with the multivariate potential scale reduction factor [32], and visually by assessing the history, chains, and autocorrelation. Vague priors were used for all parameters.

Finally, cost ingredients such as *diagnostics, outpatient care, hospitalization, emergency care, and medications* were tabulated and descriptively analyzed.

Results

Our search identified 22,778 publications from six databases and a further 12 studies from reference searches. Following deduplication, 19,027 titles/abstracts were screened with 173 eligible for full-text review. In all, 59 studies were selected in this review (Fig. 2).

Study characteristics

Charting of the study characteristics is further presented in Additional file 5. Twelve countries were represented in the 59 studies, mostly high-income countries (95%),




Fig. 2 Geographic locations of study settings and number of studies in each setting. Legend: We mapped out countries where the studies were conducted and the respective number of studies identified for each country. The color codes show the different levels of country income, according to the World Bank classification in 2021

primarily the United States (US) ($n = 44$) and Spain ($n = 4$) and one multi-country study (Table 1).

Over half of studies were cross-sectional (54%), followed by longitudinal/cohort (44%). Across the 59 studies, the primary source of data was insurance claim databases (63%). Patient survey data were used in 20

studies (34%), so were medical databases. A third of all studies linked data across multiple databases. The “other” category comprises sub-databases, for example, the cancer registry, the national inpatient sample, and the drug prescription registry [48–50]. Most articles reported direct medical costs (98%), with few reporting

Table 1 Summary characteristics of studies ($N = 59$)

Study characteristic	Articles n (%)
Type of study ($N = 59$)	
Cross-sectional	32 (54%)
Cohort/longitudinal	26 (44%)
Case-control	1 (2%)
World Bank classification ($n = 59$)	
High-income country	56 (95%)
Middle-income country	3 (5%)
Low-income country	0 (0)
Source of data ($n = 59$)*	
Insurance claim database	37 (63%)
Hospital/medical database	19 (32%)
Patient survey	20 (34%)
Linked database	20 (34%)
Other	6 (10%)
Type of costs included ($n = 59$)*	
Direct medical costs	58 (98%)
Direct non-medical costs	2 (3%)
Indirect costs	7 (12%)
Costing perspective ($n = 59$)*	
Public	48 (81%)
Household/patient	12 (20%)
Societal	8 (14%)
Provider	1 (2%)
Number of disease combination sets from all studies* ($n = 325$)	
Included in narrative synthesis (research questions 1 and 4)	229 (70%)
Included in country comparison (research question 2)	41 (13%)
Included in meta-analyses (research question 3)	34 (10%)
Number of conditions in each disease combination set ($n = 325$)	
Two	282 (87%)
More than two	43 (13%)
Frequently appeared in disease combination sets* ($n = 325$)	
Diabetes	96 (30%)
Heart/vascular conditions	93 (29%)
Mental health conditions	67 (21%)
Hypertension	59 (18%)
Respiratory conditions	52 (16%)
Cancers	38 (12%)
Quality score	Mean
Cross-sectional studies ($n = 32$)	7.8 out of 10
Cohort studies ($n = 26$)	7.9 out of 9
Case-control studies ($n = 1$)	7.0 out of 9

*Studies can belong to more than one category, meaning individual percentages at times do not sum to 100%

direct non-medical (3%) [51, 52] or indirect costs (12%) [51–57].

Quality assessment scores tended to be higher among cohort/longitudinal studies, and those which had used linked databases. All studies achieved the inclusion threshold of 5 points. Patient surveys had been used in a third of all studies. As acknowledged to contain a risk of bias (recall, language, time), most of the included studies which used patient survey (i.e., Medical Expenditure Panel Survey (MEPS)) [41, 58–63] had cross-checked collected data with administrative data [64]. Several ambiguities were observed among studies. Those using data from insurance claims databases often did not specify whether reported estimates included copayments or deductibles [65–67]. Many studies also did not specify whether the reported estimates were of adjusted or unadjusted costs, all-cause healthcare costs or disease-specific costs [60–62]. A small number of studies did not clearly specify the year of currency, the timeframe of reported costs (per patient per month/year/two years), the sample size related to the estimate, or the measure of distribution [58, 61, 65, 68]. Finally, challenges were present in making comparisons of cost ingredients across studies, with some having broader categorizations (inpatient, outpatient, emergency care, pharmacy) and some having smaller categories (diagnostics, physician, specialist) or a mix of both [43, 65, 69].

Focus of multimorbidity

While five studies had explored a wide range of disease combinations from the population or sub-population level [48, 55, 60, 66, 70], the majority of studies focused on one [33, 41, 43, 52, 53, 56, 59, 65, 71–88] or several disease combinations relating to an index disease of interest [40, 42, 49–51, 54, 57, 58, 60–62, 67–69, 73, 89–103].

Of the 325 disease combinations featured across all studies, 87% were combinations of two co-existing conditions (dyads), while 13% were combinations involving three (triads) or more co-existing conditions. A large proportion of these combinations involved diabetes (30% of combinations) and heart/vascular conditions (29%). Other diseases which featured prominently in disease combinations were mental health conditions (21%), hypertension (18%), respiratory conditions (16%), and cancers (12%).

To condense information, we selected 229 sets of disease combinations, each of which involved at least one of the above frequently reported diseases to include in the narrative synthesis. The remaining sets (highlighted in Additional file 6 — Cost conversion table) are those which either did not include one of these frequently reported diseases, those that included comorbidities not originally in our search strings, or those which had not

met our criteria for reporting mean direct cost per capita. We focused mostly on dyads. Of the 229 sets of disease combinations, 41 were selected for the country comparison and 34 for the meta-analyses. The following 11 groups were the most frequently reported combinations:

1	Cancer + Mental health condition (first year after cancer diagnosis)
2	Diabetes + Heart/vascular condition
3	Diabetes + Hypertension
4	Diabetes + Kidney disease
5	Diabetes + Mental health condition
6	Hypertension + Heart/vascular condition
7	Hypertension + Kidney disease
8	Hypertension + Musculoskeletal disorder
9	Hypertension + Respiratory condition
10	Respiratory condition + Heart/vascular condition
11	Respiratory condition + Mental health condition


Research question 1: Evidence on the costs of multimorbidity

The variation in reporting in the underlying studies presented challenges in comparing costs between different disease combinations in a homogenous way. Across the 229 sets of disease combinations, costs per year ranged from I\$827 for a TB-diabetes patient in Malaysia [71] to I\$147,784 for a patient with HIV and pulmonary circulation disorders in the US (Additional file 7: Table S2) [99]. Several studies reported high costs for multimorbidity in the last 6 months of life or the 6 months immediately after diagnosis. For example, cost in the last 6 months of life for a patient in the US with heart failure and diabetes is I\$51,145 [72], considerably higher than that of similar patients earlier in life [33, 60, 90]. Reported costs are also high when they incorporate direct non-medical and indirect costs. In the case of patients diagnosed with stroke and diabetes in Spain, the annual cost reported per patient, which included indirect costs, was I\$52,606 [51]. Of this total, direct medical costs account for merely a quarter.

Table S2: Available evidence on the costs of multimorbidity (Additional file 7)

Research question 2: The variation in costs across countries

The list of included studies in this section is in Additional file 8 — Checklist and data used for the country comparison. Studies selected for this analysis were of the same cost perspective, reported annual mean direct medical cost, and had similar cost ingredients determined by recurring ingredients (hospitalization, outpatient care, emergency care, drugs). Where appropriate, costs per month and per 24 months were multiplied by 12 and divided by 2, respectively, to arrive at the annual



estimates [40, 43, 98]. Two studies reported costs from a societal perspective; hence, we removed the indirect cost from total costs for the purpose of this analysis [53, 57].

First, log10 transformed cost per capita of multimorbidity was plotted against log10 transformed country GDP per capita using a fixed-effects model (Fig. 3). In the fixed-effects model, country GDP per capita accounts for under half of the variation in cost estimates ($R^2 = 0.47$; $p < 0.001$). Every International Dollar increase in GDP on the log10 scale is associated with an expected increase of 1.64 International Dollars in the cost of multimorbidity on the log10 scale ($p < 0.001$).

Next, we used a linear mixed model with random intercept to adjust for covariates (Table 2). Country GDP per capita accounts for a high proportion of the variation in cost estimates ($R^2 = 0.94$; $p < 0.001$). Every International Dollar increase in GDP on the log10 scale is associated with an expected increase of 1.91 International Dollars in the cost of multimorbidity on the log10 scale. In addition, given that the observations derived from different studies, *study* and *data source* accounted for 40% and 47% of the remaining variation in costs, respectively.

Research question 3: Meta-analyses of the costs of most frequently reported disease combinations and their variation

The 15 studies in the meta-analyses were selected using stringent homogeneity criteria (checklist and study

Table 2 Relationship between direct costs and GDP, adjusted model

Predictor	Estimate	Standard error
Intercept	-4.86*	1.26
Log10 GDP	1.91*	0.27
Random effects		Variance
Study	0.02029	
Data source	0.02365	
Residual	0.00684	
AIC	-31.87	
<i>R-squared adjusted</i>	0.94	
<i>N</i>	41	

Legend: We ran a linear mixed model with various study characteristics as random effects to assess the relationship between direct costs of multimorbidity and country GDP. * $p < 0.001$

details in Additional file 9 — Homogeneity checklist and data used for the meta-analyses). This resulted in a small number of data points in each sub-analysis. Random-effects models did not converge for disease combinations with a low number of studies and were not pursued further. Therefore, only results of fixed-effects models are presented for consistency. All meta-analyses resulted in I^2 values above 95%. In the absence of other analyses utilizing a richer and more homogenous evidence base, these estimates may be the most informative to date.

Table 3 Results of meta-analyses

Dyad	Pooled mean cost (I\$)	95%CI
Hypertension + Musculoskeletal disorder	13,270	(12,960–13,580)
Hypertension + Diabetes	14,300	(13,940–14,660)
Hypertension + Respiratory condition	17,180	(16,530–17,830)
Hypertension + Kidney disease	17,740	(17,060–18,420)
Hypertension + Heart/vascular condition	17,880	(17,520–18,250)
Diabetes + Mental health condition	20,750	(19,830–21,660)
Diabetes + Kidney disease	32,410	(32,370–32,440)
Respiratory + Heart/vascular condition	35,070	(34,890–35,260)
Respiratory + Mental health condition	36,840	(36,440–37,250)
Diabetes + Heart/vascular condition	37,090	(35,870–38,310)
Cancer + Mental health condition (<i>first year after cancer diagnosis</i>)	85,820	(81,930–89,690)

Legend: Mean cost data were meta-analyzed using a fixed-effects model assuming a normal likelihood for study-specific mean costs. All meta-analyses resulted in I^2 values above 95%. Costs are presented in 2021 International Dollars

Of the 11 most frequently reported dyads, patients with Cancer + Mental Health condition within the first year of cancer diagnosis had the highest average annual direct medical costs (I\$85,820) and greatest intra-group variability (Table 3). This is the only care-cascade-specific sub-group among the 11 most frequently reported dyads. The cost of this dyad is two to six times higher than that of other dyads.

Patients with Hypertension + Musculoskeletal disorder incurred the lowest average annual direct medical costs (I\$13,270), followed by patients with hypertension comorbid with diabetes (I\$14,300), respiratory condition (I\$17,180), kidney disease (I\$17,740), and heart/vascular condition (I\$17,880). In general, dyads involving hypertension were among the least expensive to manage.

Kidney disease when comorbid with hypertension resulted in a lower mean cost than when comorbid with diabetes [I\$17,740 (95% CI: 17,060–18,420) vs I\$32,410 (95%CI: 32,370–32,440)]. The 95% CI of the two mean cost estimates do not overlap; hence, the difference is statistically significant.

Mental health condition when comorbid with diabetes incurred lower mean cost than when comorbid with a respiratory condition [I\$20,750 (95% CI: 19,830–21,660) vs I\$36,840 (95% CI: 36,440–37,250)] — the difference is statistically significant. However, when comorbid with heart/vascular condition, diabetes incurred higher mean cost than respiratory condition [I\$37,090 (95% CI: 35,870–38,310) vs I\$35,070 (95% CI: 34,890–35,260)] — the difference is statistically significant.

Our results further demonstrate that the costs of multimorbidity may not be additive of individual diseases.

For example, the *average* cost of treating a patient with Diabetes + Kidney Disease (I\$32,410) is observed to be larger than the *summed cost* of treating both {a patient with Hypertension + Diabetes (I\$14,300) and a patient with Hypertension + Kidney Disease (I\$17,740)}; however, this result is not statistically significant.

Research question 4: Commonly included “cost ingredients”

Studies reporting total direct medical costs most frequently included costs of hospitalization ($n = 57$), outpatient care ($n = 56$), emergency care ($n = 50$), and drugs ($n = 40$). Other cost ingredients which were less common were those for consultations, diagnostics, surgery, medical equipment, specialist services, and therapy. For studies that reported direct non-medical costs ($n = 2$), food and transport costs were reported frequently, while costs of social care were rarely reported [51, 52]. Indirect costs ($n = 7$) principally focused on productivity loss, including wage and/or time loss, with a single study additionally including the interest from debts/loans [51–57, 89]. Detailed charting for cost ingredients is presented in Additional file 10.

Discussion

Managing multimorbidity is expensive and imposes a considerable economic burden on both the health system and society. The finding that multimorbidity costs are positively associated with a country’s wealth highlights an urgent need for more evidence on the drivers of these costs. Our review further reveals a lack of balance in multimorbidity cost literature globally, which is dominated by US-based research, accounting for seven in every ten studies. Our review further examines how existing costing studies for multimorbidity are designed, and makes important recommendations for standardization in future research.

Research question 1: Evidence on the costs of multimorbidity — and discussion of methodological issues and best practices in future costing studies

The availability of accurate and detailed costing studies will be essential in the coming decades to support global efforts to address multimorbidity. This review demonstrates, however, that there is a narrow scope of research and lack of methodological standardization contributing to variability between studies and impeding meaningful comparisons.

Specifically, focusing on index disease(s) and a few pre-selected comorbidities —for example [54, 66, 67, 69, 95] — rather than exploring the costs of possible combinations from a broader population perspective limits findings to few combinations. This makes it difficult to

understand the full spectrum of the economic burden of multimorbidity in a country and create a basis for comparison between countries.

Moreover, the majority of studies obtained their costs from standalone data sources. Such an approach cannot provide a holistic view of healthcare costs including aspects such as non-medical and indirect costs [104]. A “bottom-up” approach to estimating the costs of chronic diseases using a medico-administrative database would be optimal in costing for multimorbidity [105]. Patient surveys have been found to underestimate costs, and ultimately, these should be used in conjunction with other data sources to correct for recall bias and to capture any costs unknown to healthcare users [106]. The practice of linking health data across multiple interfaces [15] and steps to linking population health data with administrative claims database have been endorsed [107].

Furthermore, with costs markedly higher in the 6-month windows before death and after diagnosis, further studies taking a longitudinal design would provide a clearer understanding of how costs and drivers evolve along the disease trajectory [21]. Understanding these transition stages is essential in the design and targeting of appropriate interventions [27].

The clear lack of agreement on the scope of health services to include, or which ingredients should be costed, along with a diverse array of methodologies and definitions contribute to heterogeneity between studies. A recommended guideline to collecting and estimating costs of multimorbidity may help in standardizing the definitions, process, and components and reducing the level of variability between studies [21, 48].

Finally, the scarcity of studies on the cost of multimorbidity from LMICs raises concern over equity. LMICs have become the new hub for NCDs and more research is imperative to setting out priority health agendas and informing the re-organization of healthcare delivery to support patients with multiple needs [13].

Research question 2: The variation in costs across countries

To contextualize the possible drivers of the difference in costs among different country settings, we used GDP per capita as a determinant. While the data available for these analyses were again skewed by the predominance of American studies (14 out of 28 data points from the US), our regression showed that costs were generally higher in countries with higher GDP per capita [70]. Other studies on the costs of single chronic diseases such as diabetes have also pointed to similar findings [108]. This is not to be unexpected, and consistent with the fact that countries with higher GDP tend to have higher government spending on healthcare, driving up healthcare utilizations and costs [108]. However, the large variation in

cost within a country (in this case, the US) also calls for in-depth assessment of the cost drivers of multimorbidity within a health system (system-level factors). The organization of care, e.g., standard *vs* integrated care, may play an important factor, though was not reported in the studies.

The high in-group variability of the costs of dyads (even when they all originate from the US — see Additional file 8) is in part due to the fact that these dyads were constructed as generic disease groups. For example, there are various cancer sites and mental health conditions with different levels of severity, treatment, duration, etc., which results in variability in costs. Additionally, the in-group variability for costs in the US might be explained by the use of different data sources and other study characteristics (study-level factors).

Research question 3: Meta-analyses of the costs of the most frequently reported disease combinations and their variation

Although the cost of multimorbidity in part depends on the stage of the diseases alongside other factors, the knowledge of high-cost/low-cost disease combinations may inform the development of new integrated care models, where patients are classified according to their short-term/long-term need for specialist/routine care.

Using a fixed-effects model, results from the meta-analyses showed that patients with Cancer + Mental Health within the first year of cancer diagnosis had the highest average annual direct medical costs. This figure (\$85,820) is double that of another US study included in this review, which reported the cost of cancer and mental health not specific to any stage of the cascade of care (\$43,320) [103]. Indeed, treating cancers is expensive as research and development for cancer drugs and therapies are still ongoing [109] and it is even higher still during the 6–12 months following diagnosis compared to the period before or after that [110–112]. When comorbid with depression, the overall healthcare cost of treating cancer patients has been found to increase by 113% compared to non-depressed cancer patients [113].

Dyads involving hypertension were among the least expensive to manage. For patients with kidney disease, having a comorbidity of hypertension costs less than half of having a comorbidity of diabetes. Similarly, in the case of patients with a heart/vascular condition, having hypertension costs around half of having a respiratory condition. Specifically among hypertensive patients, treatment for musculoskeletal disorder *or* diabetes is cheaper than kidney disease *or* heart/vascular condition. A study found that based on the number of episodes that occurred within a period, and the frequency of transition from primary to specialist or emergency care, conditions such

as hypertension may indicate “low severity of healthcare impact” and conditions such as kidney disease, heart/vascular disease, and respiratory disease may indicate “high severity”; thus the effect on costs [13]. Many chronic conditions feature commonly in multimorbidity dyads, and whether the cost of a disease combination is more or less than the additive costs of the component diseases needs to be further explored.

Although all studies included in the meta-analyses originated from the US, our findings provide valuable data on the differences in costs for treating different disease combinations within the American healthcare system. Though healthcare systems vary considerably between countries, the difference in costs between these 11 dyads in the US provides an indication of how they may be in other countries; however, more research in this area is needed.

Research question 4: Commonly included “cost ingredients”

Our review highlights several missing pieces of the multimorbidity burden puzzle, notably that non-medical and indirect costs of multimorbidity are often not costed for. Particularly, social care is considered an important element of care for multimorbid patients given the long-term spectrum and complexity of illness, which may have lasting effects on their care needs [114]. In some settings, research has shown that social care cost may drive total care cost more than healthcare cost itself [18]. However, costing studies on multimorbidity which examine the component of social care/home care are still by and large limited [18, 115, 116]. This aspect is critical to understanding the full spectrum of multimorbidity costs to the system, especially when this has implications for vulnerable groups in society [27].

The most frequently reported cost ingredients identified were outpatient, inpatient, emergency care, and drugs. However, across studies, certain cost ingredients may overlap with one another (e.g., outpatient and GP visits, hospitalization and inpatient services, diagnostics and testing). Due to the ambiguous use of terms, it is difficult to clearly pinpoint the definition of the specific cost ingredients and what they entail.

Strengths and limitations

To the best of our knowledge, our review is the first to systematically collect and quantitatively synthesize costs for disease combinations with comparability. We screened a large number of articles having conducted an extensive search. Beyond answering our research questions, we have additionally provided valuable insights into commonalities and inconsistencies in underlying

methodologies between studies, and the ways in which these studies reported costs.

Our study also has several limitations. Firstly, our categorizations of diseases were made in line with health system organizational considerations, grouping conditions at an organ system level within medical specialties. This enabled us to reduce the number of combinations enabling meaningful interpretations; however, alternate groupings would have been possible, and those following a more treatment-focused perspective may have led to variation in results. On the other hand, we categorized *hypertension* separately from the heart/vascular group as it is a major risk factor for the latter. Most studies also report hypertension separately; therefore, following this approach allows for cross-comparison between studies.

In the meta-analyses, the degree of heterogeneity and variation of the underlying studies limited the number of studies included, all of which were from the US. Several sub-group analyses (e.g., Respiratory + Mental health, Respiratory + Heart/vascular condition) comprised only two data points. This may have limited the plausibility of the assumed approximated normality of mean costs. Furthermore, high I^2 values were estimated for all disease combinations indicating a high degree of between-studies heterogeneity. Despite this, these results may still provide the best available insights though need to be interpreted in light of the highlighted methodological challenges.

The limited availability of studies from other countries led to the country comparison being dominated by studies from the US, with variation in these costs. More data from other countries are required to further examine this relationship.

Overall, we acknowledge that costs of multimorbidity may depend on many different factors including and beyond those that have been discussed in this paper. These may include individual-level factors (e.g., socio-demographic characteristics of patients, the number and severity of comorbidities, type and duration of healthcare intervention, access to care), system-level factors (e.g., the country, health system financing structure, level of care — e.g., public vs private, primary vs secondary care), and study-level factors (e.g., sampling error, costing perspective, data source, choice of cost ingredients). These details, however, were frequently unavailable, or not available to a sufficient level (e.g., severity of conditions, duration of care, type of health facility, etc.) to allow for structural reporting. Therefore, we were unable to control for some of these factors in the analysis. Despite these limitations, our review has revealed important findings.

Conclusions

This review provides valuable insights into the costs across multimorbid health profiles, highlighting where priorities should be aligned to combat the escalating and complex economic burden of multimorbidity. These timely findings are essential for informing both the implementation of health interventions and the restructuring of healthcare delivery for multimorbid patients.

Multimorbidity imposes a large economic burden on both the health system and society, most notably for patients with cancer and mental health condition in the first year after cancer diagnosis. Whether the cost of a disease combination is more or less than the additive costs of the component diseases needs to be further explored.

The scope of research on the costs of multimorbidity is still narrow. Previous studies have typically only considered a narrow range of disease combinations, with data often obtained from single sources. Research to date has originated from a small pool of countries, with a striking lack of costing studies on multimorbidity from LMICs and Europe. Further rigorous and standardized methods of data collection and costing are essential to provide more comprehensive and comparable evidence of the cost of multimorbidity.

Abbreviations

AIC: Akaike Information Criterion; COPD: Chronic obstructive pulmonary disease; GDP: Gross Domestic Product; I\$: International dollars; LMICs: Low- and middle-income countries; MEPS: Medical Expenditure Panel Survey; NCDs: Noncommunicable diseases; NOS: Newcastle–Ottawa Quality Assessment; PPP: Purchasing Power Parities; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; TB: Tuberculosis; US: United States.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12916-022-02427-9>.

- Additional file 1.** Search strings
- Additional file 2.** Screening checklists
- Additional file 3.** Data cleaning flow chart
- Additional file 4.** Definition of terminologies
- Additional file 5.** Charting of study characteristics
- Additional file 6.** The cost conversion table
- Additional file 7: Table S2.** Evidence on the costs of multimorbidity
- Additional file 8.** Checklist and data used for the country comparison
- Additional file 9.** Homogeneity checklist and data used for the meta-analyses
- Additional file 10.** Charting of cost ingredients

Acknowledgements

We would like to thank Barbara Lejeune from the University of Antwerp Library Committee Faculty (Antwerp, Belgium) for her valuable support in building the search strings and running the initial search. We would like to thank the COSMOS team for providing us with important background

information on chronic diseases. COSMOS is part funded by the National Institute for Health Research (NIHR) (Grant 17/63/130 NIHR Global Health Research Group: Improving Outcomes in Mental and Physical Multimorbidity and Developing Research Capacity (IMPACT) in South Asia at the University of York) using UK aid from the UK Government to support global health research. We would also like to thank Barouma Ifigeneia, MSc from IQVIA (London, UK) for her technical support and expert insights in conducting the meta-analyses. Finally, we would like to thank Ewan Morgan Tomeny, MSc, from Liverpool School of Tropical Medicine (Liverpool, UK) for proofreading the manuscript and providing valuable advice for the improvement of the paper.

Authors' contributions

PT, JK, and JVO devised the review strategy. PT, JK, and BL developed the search string and conducted the search. PT and JK performed the review of the literature and extracted data. PT performed the analysis with the support of JK. GN guided part of the analysis and provided technical support. PT composed the manuscript. JVO, MR, and IL provided technical support and insights. JVO supervised the overall process. All authors contributed in the revision of the manuscript and approved the final version.

Authors' information

Phuong Bich Tran is a PhD student in Medical Sciences at the University of Antwerp, Belgium. This publication is a component of her PhD project on multimorbidity.

Funding

The research is financed by the BOF-DOCPRO grant, University of Antwerp.

Availability of data and materials

Data and materials will be made available upon request.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Family Medicine and Population Health, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. ²Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden. ³Department of Global Health, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK. ⁴IQVIA Ltd., 37 North Wharf Road, London W2 1AF, UK. ⁵Department of Health and Social Management, University of Eastern Finland, Kuopio, Finland. ⁶Netherlands Institute for Health Services Research, Utrecht, The Netherlands.

Received: 25 September 2021 Accepted: 6 June 2022

Published online: 19 July 2022

References

1. Volksgezondheidszorg. Chronic conditions and multimorbidity 2019. In: Nivel Primary Care Registers. 2020. Available: <https://www.volksgezondheidszorg.info/onderwerp/chronische-aandoening-en-en-multimorbiditeit/cijfers-context/huidige-situatie#node-prevallentie-multimorbiditeit-naar-aantal-chronische-aandoeningen>. Accessed 5 Sept 2021.
2. Fortin M, et al. Prevalence of multimorbidity among adults seen in family practice. *Ann Fam Med*. 2005;3(3):223–8.
3. Garin N, et al. Multimorbidity patterns in a national representative sample of the Spanish adult population. *PLoS One*. 2014;9(1):e84794.
4. Lim SS, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21

- regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380(9859):2224–60.
5. Souza DLB, et al. Trends of multimorbidity in 15 European countries: a population-based study in community-dwelling adults aged 50 and over. *BMC Public Health*. 2021;21(1):76.
 6. Abebe F, et al. Multimorbidity of chronic non-communicable diseases in low- and middle-income countries: a scoping review. *J Comorb*. 2020;10:2235042X20961919.
 7. The Academy of Medical Sciences. Multimorbidity: a priority for global health research. The Academy of Medical Sciences; 2018. Available: <https://acmedsci.ac.uk/file-download/82222577>. Accessed 3 July 2021.
 8. McPhail SM. Multimorbidity in chronic disease: impact on health care resources and costs. *Risk Manag Healthc Policy*. 2016;9:143–56.
 9. Afshar S, Roderick P, Kowal P, Dimitrov B, Hill A. Global patterns of multimorbidity: a comparison of 28 countries using the world health surveys. In: *Applied demography and public health in the 21st century*. 2017. p. 381–402. Available: <https://www.researchgate.net/publication/308967883>. Accessed 17 May 2021.
 10. Bloom DE, Chen S, McGovern ME. The economic burden of noncommunicable diseases and mental health conditions: results for Costa Rica, Jamaica, and Peru. *Rev Panam Salud Publica*. 2018;42:e18.
 11. Fox MH, Reichard A. Disability, health, and multiple chronic conditions among people eligible for both Medicare and Medicaid, 2005–2010. *Prev Chronic Dis*. 2013;10:E157.
 12. Prados-Torres A, et al. Multimorbidity patterns: a systematic review. *J Clin Epidemiol*. 2014;67(3):254–66.
 13. Sinnige J, et al. The prevalence of disease clusters in older adults with multiple chronic diseases—a systematic literature review. *PLoS One*. 2013;8(11):e79641.
 14. Violan C, et al. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. *PLoS One*. 2014;9(7):e102149.
 15. Kadam UT, et al. Chronic disease multimorbidity transitions across healthcare interfaces and associated costs: a clinical-linkage database study. *Bmj Open*. 2013;3(7):9.
 16. Palladino R, et al. Associations between multimorbidity, healthcare utilisation and health status: evidence from 16 European countries. *Age Ageing*. 2016;45(3):431–5.
 17. Cabral GG, et al. Multimorbidity and its impact on workers: a review of longitudinal studies. *Saf Health Work*. 2019;10(4):393–9.
 18. Picco L, et al. Economic burden of multimorbidity among older adults: impact on healthcare and societal costs. *BMC Health Serv Res*. 2016;16:173.
 19. Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition—multimorbidity. *JAMA*. 2012;307(23):2493–4.
 20. Cai M, et al. Comparing the performance of Charlson and Elixhauser Comorbidity Indices to predict in-hospital mortality among a Chinese population. *Clin Epidemiol*. 2020;12:307–16.
 21. Wang L, et al. A systematic review of cost-of-illness studies of multimorbidity. *Appl Health Econ Health Policy*. 2018;16(1):15–29.
 22. Lehnert T, et al. Review: health care utilization and costs of elderly persons with multiple chronic conditions. *Med Care Res Rev*. 2011;68(4):387–420.
 23. Shamseer L, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*. 2015;350:g7647.
 24. Ouzzani M, et al. Rayyan—a web and mobile app for systematic reviews. *Syst Rev*. 2016;5(1):210.
 25. Wells GA, D O'Connell BS, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 4 Sept 2020.
 26. Model Systems Knowledge Translation Center. Using REDCap for systematic reviews. Available from: https://libguides.usc.edu/ld.php?content_id=56738700. Accessed 19 June 2020.
 27. Kazibwe J, Tran PB, Annerstedt KS. The household financial burden of non-communicable diseases in low- and middle-income countries: a systematic review. *Health Res Policy Syst*. 2021;19(1):96.
 28. World Bank. What is an “international dollar”? Available: <https://datahelpdesk.worldbank.org/knowledgebase/articles/114944-what-is-an-international-dollar>. Accessed 10 Mar 2022.
 29. Inflation tool. Available: <https://www.inflationtool.com/>. Accessed 29 Jan 2021.
 30. OECD. Purchasing power parities (PPP). Available: <https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm>. Accessed 29 Jan 2021.
 31. Kim DD, et al. Perspective and costing in cost-effectiveness analysis, 1974–2018. *Pharmacoeconomics*. 2020;38(10):1135–45.
 32. Garrison LP Jr, et al. An overview of value, perspective, and decision context—a health economics approach: an ISPOR Special Task Force Report [2]. *Value Health*. 2018;21(2):124–30.
 33. Visaria J, et al. Healthcare costs of diabetes and microvascular and macrovascular disease in individuals with incident type 2 diabetes mellitus: A ten-year longitudinal study. *ClinicoEconomics Outcomes Res*. 2020;12:423–34.
 34. GBD. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016;388(10053):1659–724.
 35. O'Neill D, et al. Stroke is a chronic disease with acute events. *BMJ*. 2008;336(7642):461.
 36. World Health Organization. Noncommunicable diseases. 2021. Available: <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases>. Accessed 26 Jan 2022.
 37. World Bank. GDP per capita (current US\$). Available: <https://data.worldbank.org/indicator/NY.GDP.PCAP.CD>. Accessed 10 Mar 2022.
 38. National Statistics Republic of China (Taiwan). National Account. Available: <https://eng.stat.gov.tw/np.asp?CtNode=1539>. Accessed 10 Mar 2022.
 39. RStudio. RStudio 2021.09.0 Update: What's New. 2021. Available: <https://www.rstudio.com/blog/rstudio-2021.09.0-update-whats-new/>. Accessed 31 Oct 2021.
 40. Annavarapu S, et al. Health care resource utilization among patients with T2D and cardiovascular-, heart failure-, or renal-related hospitalizations. *Am J Managed Care*. 2020;26(6):e166–71.
 41. Egede LE, et al. Trends in costs of depression in adults with diabetes in the United States: medical expenditure panel survey, 2004–2011. *J Gen Intern Med*. 2016;31(6):615–22.
 42. Niazi S, et al. Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma. *Blood Advances*. 2018;2(10):1120–8.
 43. Mehta S, et al. Differences in all-cause health care utilization and costs in a type 2 diabetes mellitus population with and without a history of cardiovascular disease. *J Managed Care Specialty Pharm*. 2018;24(3):280–+.
 44. Mihaylova B, et al. Review of statistical methods for analysing health-care resources and costs. *Health Econ*. 2011;20(8):897–916.
 45. Gelman A. Prior distributions for variance parameters in hierarchical models. *Bayesian Analysis*. 2006;1(3):515–33.
 46. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.3 (updated February 2022). Cochrane, 2022. Available: <https://training.cochrane.org/handbook/current>. Accessed 8 Mar 2022.
 47. MRC Biostatistics Unit. The BUGS project 2010. Available: <https://www.mrc-bsu.cam.ac.uk/software/bugs/the-bugs-project-winbugs/>. Accessed 5 Apr 2021.
 48. Blakely T, et al. Health system costs for individual and comorbid non-communicable diseases: an analysis of publicly funded health events from New Zealand. *PLoS Med*. 2019;16(1):e1002716.
 49. Carstensen J, et al. How does comorbidity influence healthcare costs? A population-based cross-sectional study of depression, back pain and osteoarthritis. *BMJ Open*. 2012;2(2):e000809.
 50. Figueroa JF, et al. International comparison of health spending and utilization among people with complex multimorbidity. *Health Serv Res*. 2021;56(Suppl 3):1317–34.
 51. Alvarez-Sabin J, et al. Economic impact of patients admitted to stroke units in Spain. *Eur J Health Econ*. 2017;18(4):449–58.
 52. Mudzengi D, et al. The patient costs of care for those with TB and HIV: a cross-sectional study from South Africa. *Health Policy Plan*. 2017;32:iv48–56.
 53. de Miguel-Diez J, et al. The influence of heart disease on characteristics, quality of life, use of health resources, and costs of COPD in primary care settings. *BMC Cardiovasc Disord*. 2010;10:8.

54. MacNeil-Vroomen JL, et al. Health-care use and cost for multimorbid persons with dementia in the National Health and Aging Trends Study. *Alzheimer's Dement*. 2020;16(9):1224–33.
55. Meraya AM, Sambamoorthi U. Chronic condition combinations and productivity loss among employed nonelderly adults (18 to 64 Years). *J Occup Environ Med*. 2016;58(10):974–8.
56. Sicras Mainar A, Navarro Artieda R, Ibanez Nolla J. Economic impact of heart failure according to the effects of kidney failure. *Revista Espanola de Cardiologia*. 2015;68(1):39–46.
57. Sicras-Mainar A, Navarro-Artieda R, Ibanez-Nolla J. Clinical and economic characteristics associated with type 2 diabetes. *Revista Clinica Espanola*. 2014;214(3):121–30.
58. Armbrecht E, et al. Economic and humanistic burden associated with noncommunicable diseases among adults with depression and anxiety in the United States. *J Med Econ*. 2020;23(9):1032–42.
59. Egede LE, et al. Impact of diagnosed depression on healthcare costs in adults with and without diabetes: United States, 2004–2011. *J Affect Disord*. 2016;195:119–26.
60. Meraya AM, Raval AD, Sambamoorthi U. Chronic condition combinations and health care expenditures and out-of-pocket spending burden among adults, medical expenditure panel survey, 2009 and 2011. *Prev Chronic Dis*. 2015;12:13.
61. Lekoubou A, Bishu KG, Ovbiagele B. Nationwide healthcare expenditures among hypertensive individuals with stroke: 2003–2014. *J Stroke Cerebrovasc Dis*. 2018;27(7):1760–9.
62. Park C, et al. Comorbidity status and annual total medical expenditures in U.S. hypertensive adults. *Am J Prev Med*. 2017;53(6):S172–81.
63. Wang G, et al. Annual total medical expenditures associated with hypertension by diabetes status in U.S. adults. *Am J Prev Med*. 2017;53(6):S182–9.
64. Cohen JW, S. BC, Banthan JS. The medical expenditure panel survey: a national information resource to support healthcare cost research and inform policy and Practice. *Med Care*. 2009;47:S44–50.
65. Maggioni AP, et al. Prevalence, prescriptions, outcomes and costs of type 2 diabetes patients with or without prior coronary artery disease or stroke: a longitudinal 5-year claims-data analysis of over 7 million inhabitants. *Ther Adv Chronic Dis*. 2021;12:20406223211026390.
66. Majumdar UB, et al. Multiple chronic conditions at a major urban health system: a retrospective cross-sectional analysis of frequencies, costs and comorbidity patterns. *BMJ Open*. 2019;9(10):e029340.
67. Lin PJ, Shaya FT, Scharf SM. Economic implications of comorbid conditions among Medicaid beneficiaries with COPD. *Respir Med*. 2010;104(5):697–704.
68. Nichols GA, et al. Medical care costs among patients with established cardiovascular disease. *Am J Managed Care*. 2010;16(3):e86–93.
69. Li R, et al. Medical costs associated with type 2 diabetes complications and comorbidities. *Am J Managed Care*. 2013;19(5):421–30.
70. Yoon J, et al. Costs associated with multimorbidity among VA patients. *Med Care*. 2014;52(3):S31–6.
71. Aweis DMI, Syed Azhar SS. Economic burden of diabetic tuberculosis patients. *Br J Med Res*. 2013;3(4):1598–606.
72. Blecker S, Herbert R, Brancati FL. Comorbid diabetes and end-of-life expenditures among Medicare beneficiaries with heart failure. *J Card Fail*. 2012;18(1):41–6.
73. Boye KS, Lage MJ, Terrell K. Healthcare outcomes for patients with type 2 diabetes with and without comorbid obesity. *J Diabetes Complications*. 2020;34:107730.
74. Dalal AA, et al. Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population. *Copd*. 2011;8(4):293–9.
75. Dalal AA, et al. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. *Respir Med*. 2011;105(10):1516–22.
76. Dismuke-Greer CE, et al. Comorbid TBI-depression costs in veterans: a chronic effect of neurotrauma consortium (CENC) study. *Brain Injury*. 2019;33(2):198–204.
77. Huang CJ, et al. Health care utilization and expenditures of persons with diabetes comorbid with anxiety disorder: a national population-based cohort study. *Gen Hosp Psychiatr*. 2015;37(4):299–304.
78. Johnston SS, et al. Association of body mass index and osteoarthritis with healthcare expenditures and utilization. *Obes Sci Pract*. 2020;6(2):139–51.
79. Lekoubou A, Bishu KG, Ovbiagele B. Costs and cost-drivers of a diagnosis of depression among adults with epilepsy in the United States. *Epilepsy Behav*. 2019;98:96–100.
80. Li N, Chan E, Peterson S. The economic burden of depression among adults with rheumatoid arthritis in the United States. *J Med Econ*. 2019;22(4):372–8.
81. Mausbach BT, Bos T, Irwin SA. Mental health treatment dose and annual healthcare costs in patients with cancer and major depressive disorder. *Health Psychol*. 2018;37(11):1035–40.
82. Raval AD, Sambamoorthi U. Incremental healthcare expenditures associated with thyroid disorders among individuals with diabetes. *J Thyroid Res*. 2012;2012:418345.
83. Schwarzkopf L, et al. Impact of chronic ischemic heart disease on the health care costs of COPD patients - an analysis of German claims data. *Respir Med*. 2016;118:112–8.
84. Shrestha SS, et al. Medical expenditures associated with major depressive disorder among privately insured working-age adults with diagnosed diabetes in the United States, 2008. *Diabetes Res Clin Pract*. 2013;100(1):102–10.
85. Wang G, et al. Annual total medical expenditures associated with hypertension by diabetes status in U.S. adults. *Am J Prev Med*. 2017;53(6S2):S182–9.
86. Wen L, et al. Comparing the economic burden of ischemic stroke patients with and without atrial fibrillation: a retrospective study in Beijing, China. *Curr Med Res Opin*. 2017;33(10):1789–94.
87. Rasendran C, Imran Y, Talcott KE. Incremental economic burden of depression in ophthalmic patients. *Am J Ophthalmol*. 2021;229:184–93.
88. Rustgi VK, et al. Health care resource use and cost burden of chronic kidney disease in patients with chronic liver disease: a real-world claims analysis. *Hepatol Commun*. 2020;4(10):1404–18.
89. Ajmera M, et al. Explaining the increased health care expenditures associated with gastroesophageal reflux disease among elderly Medicare beneficiaries with chronic obstructive pulmonary disease: a cost-decomposition analysis. *Int J Copd*. 2014;9:339–48.
90. Edelman S, et al. Burden of cardiovascular disease in adult patients with type 1 diabetes in the US. *PharmacoEconomics Open*. 2020;4(3):519–28.
91. Egede LE, et al. Differential impact of mental health multimorbidity on healthcare costs in diabetes. *Am J Managed Care*. 2015;21(8):535–44.
92. Epstein AJ, et al. Changes in healthcare spending after diagnosis of comorbidities among endometriosis patients: a difference-in-differences analysis. *Adv Ther*. 2017;34(11):2491–502.
93. Hershman DL, et al. Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials. *Breast Cancer Res Treat*. 2019;181(2):455–63.
94. Hong YR, et al. Excess costs and economic burden of obesity-related cancers in the United States. *Value Health*. 2019;22(12):1378–86.
95. Mannino DM, et al. Economic burden of COPD in the presence of comorbidities. *Chest*. 2015;148(1):138–50.
96. Min JY, et al. Direct medical costs of hypertension and associated comorbidities in South Korea. *Int J Cardiol*. 2014;176(2):487–90.
97. Salber PR, et al. Impact of dementia on costs of modifiable comorbid conditions. *Am J Managed Care*. 2018;24(11):e344–51.
98. Vasiliadis HM, et al. Healthcare costs in chronically ill community-living older adults are dependent on mental disorders. *J Public Health*. 2016;38(4):e563–70.
99. Zingmond DS, et al. The cost of comorbidities in treatment for HIV/AIDS in California. *PLoS One*. 2017;12(12):e0189392.
100. Kangethe A, et al. Incremental burden of comorbid major depressive disorder in patients with type 2 diabetes or cardiovascular disease: a retrospective claims analysis. *BMC Health Serv Res*. 2021;21(1):778.
101. Olufade T, et al. Cardiovascular and renal disease manifestation and healthcare resource utilization in patients on first-line oral therapy for type 2 diabetes: A claims-based observational cohort study. *Diabetes Obes Metab*. 2021;23(12):2741–51.
102. Folkerts K, et al. Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease

- within a large U.S. administrative claims database. *J Manag Care Spec Pharm.* 2020;26(12):1506–16.
103. Jeffery DD, et al. Mental health comorbidities and cost/utilization outcomes in head and neck cancer patients. *J Psychosoc Oncol.* 2019;37(3):301–18.
 104. Sambamoorthi U, Tan X, Deb A. Multiple chronic conditions and health-care costs among adults. *Expert Rev Pharmacoecon Outcomes Res.* 2015;15(5):823–32.
 105. Cortaredona S, Ventelou B. The extra cost of comorbidity: multiple illnesses and the economic burden of non-communicable diseases. *BMC Med.* 2017;15(1):216.
 106. Leggett LE, et al. Measuring resource utilization: a systematic review of validated self-reported questionnaires. *Medicine (Baltimore).* 2016;95(10):e2759.
 107. Gontijo Guerra S, Berbiche D, Vasiliadis HM. Measuring multimorbidity in older adults: comparing different data sources. *BMC Geriatr.* 2019;19(1):166.
 108. Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. *Pharmacoeconomics.* 2015;33(8):811–31.
 109. Leigh NB, S.N., Doreen A. Ezeife, and Bishal Gyawali, An arm and a leg: the rising cost of cancer drugs and impact on access. *Am Soc Clin Oncol Educ Book.* 2021;41:e1–e12.
 110. Laudicella M, Walsh B, Burns E, et al. Cost of care for cancer patients in England: evidence from population-based patient-level data. *Br J Cancer.* 2016;114:1286–92.
 111. Goldsbury DE, Y. S, Weber MF, Veerman L, Rankin N, Banks E, et al. Health services costs for cancer care in Australia: estimates from the 45 and Up Study. *PLoS One.* 2018;13(7):e0201552.
 112. Larissa Schwarzkopf MW, Holle R, Leidl R, Günster C, Adler J-B, Huber RM. Cost-components of lung cancer care within the first three years after initial diagnosis in context of different treatment regimens. *Lung Cancer.* 2015;90(2):274–80.
 113. Mausbach BT, Y. P, Bos T, Irwin SA. Health care costs of depression in patients diagnosed with cancer. *Psychooncology.* 2018;27(7):1735–41.
 114. Rijken M, Struckmann V, van der Heide I et al., authors; Richardson E, Van Ginneken E, editors. How to improve care for people with multimorbidity in Europe? Copenhagen (Denmark): European Observatory on Health Systems and Policies; 2017. (Policy Brief, No. 23.) Available from: <https://www.ncbi.nlm.nih.gov/books/NBK464548/>.
 115. Hans-Helmut König HL, Bickel H, Fuchs A, Gensichen J, Maier W, Mengenthal K, et al. Effects of multiple chronic conditions on health care costs: an analysis based on an advanced tree-based regression model. *BMC Health Serv Res.* 2013;13:219.
 116. Asmus-Szepesi KJ, et al. Formal and informal care costs of hospitalized older people at risk of poor functioning: a prospective cohort study. *Arch Gerontol Geriatr.* 2014;59(2):382–92.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

